Interferon: 50 years later (1957-2007);Interferón: 50 años después (1957-2007)

Gaceta Medica de Mexico

Volumn 144, Issue 1, 2008, Pages 55-65

  Ramos Bello, Dolores ^a   Ramos Niembro, Francisco ^b  

^a Medicina UANL   (Mexico)

^b UNIVERSIDAD VERACRUZANA   (Mexico)

Author keywords

Cytokines; Interferon; Pleiotropic function

Indexed keywords

ALPHA INTERFERON; ALPHA1 INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHAN3 INTERFERON; BETA INTERFERON; BETA1A INTERFERON; GAMMA INTERFERON; GAMMA1B INTERFERON; INTERFERON; INTERFERON BETA SERINE; MEMBRANE RECEPTOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B;

ANAPHYLAXIS; ANEMIA; ANGINA PECTORIS; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTHRALGIA; AUTOIMMUNITY; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; CARDIOTOXICITY; CHOREA; CONFUSION; CONVULSION; CYANOSIS; DEPRESSION; DERMATITIS; DIAPHORESIS; DIARRHEA; DRUG MECHANISM; DYSESTHESIA; ECZEMA; ERYTHEMA; FATIGUE; FEVER; GLOMERULOSCLEROSIS; HEADACHE; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTRICHOSIS; HYPERTRIGLYCERIDEMIA; HYPOTENSION; IMMUNE SYSTEM; IMMUNOREGULATION; INTERSTITIAL PNEUMONIA; LETHARGY; LEUKEMIA; LEUKOPENIA; LIVER TOXICITY; MELANOMA; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NEPHROTIC SYNDROME; NEPHROTOXICITY; NEUROTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEINURIA; PRURITUS; PSYCHOSIS; PURPURA; RASH; RETINA ISCHEMIA; REVIEW; SARCOIDOSIS; SIDE EFFECT; SKIN TOXICITY; SOMNOLENCE; SUICIDE ATTEMPT; TACHYCARDIA; TELANGIECTASIA; THROMBOCYTOPENIA; TREATMENT INDICATION; URTICARIA; VERTIGO; VIRUS INFECTION;

EID: 50849117512     PISSN: 00163813     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (137)

1. Isaacs A, Burke DC. Viral interference and interferon. Br Med Bull 1959;15:185-188.
2. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957;147:258-267.
3. Isaacs A, Lindenmann J, Valentine RC. Virus interference. II. Some properties of interferon. Proc R Soc Lond B Biol Sci 1957;147:268-273.
4. Kalvakolanu DV, Borden EC. An overview of the interferon system: signal transduction and mechanism of action. Cancer Invest 1996;14:25-53.
5. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001;6:34-55.
6. Johnson HM, Bazer FW, Szente BE, Jarpe MA. How interferons fight disease. Sci Am 1994;270:68-75.
7. Theofilopoulus AN, Baccala R, Beutler B, Kono DH. Type I interferons (α/β) in immunity and autoimmunity. Annu Rev Immunol 2005;23:307-336.
8. Decker T, Muller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol 2005;5:675-687.
9. Billiau A. Interferon: the pathways of discovery I. Molecular and cellular aspects. Cytokine Growth Factor Rev 2006;17:381-409.
10. Billiau A. Anti-inflammatory properties of type I interferons. Antiviral Res 2006;71:108-116.
11. Ho M. Inteferon-like viral inhibitor in rabbits after intravenous administration of endotoxin. Science 1964;146:1472-1474.
12. Wheelock EF. IFN-like virus inhibitor induced in human leukocytes by phytohemagglutinin. Science 1965;141:130-141.
13. Field AK, Lampson GP, Tytell AA, Nemes MM, Hilleman MR. Inducers of interferon and host resistance, IV. Double-stranded replicative form RNA (MS2-Ff-RNA) from E. coli infected with MS2 coliphage. USA: Proc Natl Acad Sci 1967;58:2102-2108.
14. Gresser I. The effect of interferon preparations on friend leukemia of mice. Bibl Haematol 1968;30:37-39.
15. Gresser I, Berman L, De The G, Brouty-Boye D, Coppey J, Falcoff E. Interferon and murine leukemia. V. Effect of interferon preparations on the evolution of Rauscher disease in mice. J Natl Cancer Inst 1968;41:505-522.
16. Havell EA, Berman B, Ogburn CA, Berg K, Paucker K, Vilcek J. Two antigenically distinct species of human interferon. USA: Proc Natl Acad Sci 1975;72:2185-187.
17. Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976;295:517-522.
18. Horoszewicz JS, Leong SS, Ito M, Buffett RF, Karakousis C, Holyoke E, et al. Human fibroblast interferon in human neoplasia: clinical and laboratory study. Cancer Treat Rep 1978;62:1899-1906.
19. Taniguchi T, Fujii-Kuriyama Y, Muramatsu M. Molecular cloning of human interferon cDNA. USA: Proc Natl Acad Sci 1980;77:4003-4006.
20. Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsodi J, et al. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 1980;284:316-320.
21. Knight E Jr, Hunkapiller MW, Korant BD, Hardy RW, Hood LE. Human fibroblast interferon: amino acid analysis and amino terminal amino acid sequence. Science 1980;207:525-526.
22. Zoon KC, Smith ME, Bridgen PJ, Anfinsen CB, Hunkapiller MW, Hood LE. Amino terminal sequence of the major component of human lymphoblastoid interferon. Science 1980;207:527-528.
23. Anonymous. Interferon nomenclature. Nature 1980;286:110.
24. Jacobs L, O'Malley J, Freeman A, Ekes R. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 1981;214:1026-1028.
25. Gray PW, Goeddel DV. Structure of the human immune interferon gene. Nature 1982;298:859-863.
26. Krown SE, Real FX, Cunningham-Rundles S, et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 1983;308:1071-1076.
27. Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984;310:15-18.
28. Fentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL. Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet 1985;1:1166.
29. Burman P, Karison A, Öberg K. Autoimmune thyroid disease in interferon treated patients. Lancet 1985;2:100-101.
30. Bhakri H, Sriskandan K, Davis T, Pettingale K, Tee D. Recombinant gamma interferon and autoimmune thyroid disease. Lancet 1985;2:457.
31. Novick D, Orchansky P, Revel M, Rubinstein M. The human IFN-γ receptor. Purification, characterization and preparation of antibodies. J Biol Chem 1987;262:8483-8487.
32. Aguet M, Merlin G. Purification of human IFN-γ receptors by sequential affinity chromatography on immobilized monoclonal antireceptor antibodies and human IFN-γ. J Exp Med 1987;165;988-999.
33. Aguet M, Dembic Z, Merlin G. Molecular cloning and expression of the human IFN-γ receptor. Cell 1988;55:273-280.
34. Calderon J, Sheehan KCK, Chance C, Thomas ML, Schreiber RD. Purification and characterization of the human IFN-γ receptor from placenta. USA: Proc Natl Acad Sci 1988; 85:4837-4841.
35. Ezekowitz RA, Dinauer MC, Jaffe HS, Orkin SH, Newburger PE. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N Engl J Med 1988;319:146-151.
36. Sechler JM, Malech HL, White CJ, Gallin JI. Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. USA: Proc Natl Acad Sci 1988;85:4874-4878.
37. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-510.
38. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321:1501-1506.
39. Key LL Jr, Ries WL, Rodriguiz RM, Hatcher HC. Recombinant human interferon gamma therapy for osteopetrosis. J Pediatr 1992;121:119-124.
40. Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 1992;70:313-322.
41. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732-738.
42. Villader-Palacin A. Las citocinas en las enfermedades autoinmunes. Madrid, España: IDEPSA; 1998.
43. Diaz MO, Bohlander S, Allen G. Nomenclature of human interferon genes. J Interferon Res 1993;13:443.
44. Sen G, Ransohoff RM. Inteferon-induced antiviral actions and their regulation. Adv Virus Res 1993;42:57-101.
45. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007;13:543-551.
46. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14:778-809.
47. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004;202:8-32.
48. Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol 2003;39:S93-S98.
49. Rönnblom L, Eloranta ML, Alm GW. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006;54:408-420.
50. Grandér D. How does interferon-alpha exerts its antitumor activity in multiple myeloma? Acta Oncologica 2000;39:801-805.
51. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002;13:95-109.
52. Veldhuis WB, Floris S, van der Meide PH, Vos IM, de Vries HE, Dijkstra CD, et al. Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption. J Cereb Blood Flow Metab 2003;23:1060-1069.
53. Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y. Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum 1999;42:90-99.
54. Abreu SL. Suppression of experimental allergic encephalomyelitis by interferon. Immunol Commun 1982;11:1-7.
55. Calabresi PA, Tranquill LR, Dambrosia JM, Stone LA, Maloni H, Bash CN, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol 1997;41:669-674.
56. Trojano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, Liguori M, et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999;53:1402-1408.
57. Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999;53:1397-1401.
58. Branca AA, Faltynek CR, D'Alessandro SB, Baglioni C. Interaction of interferon with cellular receptors. Internalization and degradation of cell-bound interferon. J Biol Chem 1982;257:13291-1326.
59. Stark GR, Kerr IM, Williams RB, Silverman RH, Schreiber R. How cells responds to inteferons. Annu Rev Biochem 1998;67:227-264.
60. Levy DE, Darnell JE Jr. STATs: transcriptional control and biological impact. Nature Rev Cel Biol 2002;3:651-662.
61. Zwarthohoff EC. Interferon-α In: Roitt IM, Delves PJ. Eds. Encyclopedia of immunology. London: Academic Press; 1992. pp. 886-888.
62. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004;5:1219-1226.
63. Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998;58:2489-2499.
64. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;301:5-8.
65. Bengtsoon AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-671.
66. Dall'era MC, Cardarelli PM, Preston BY, Witte A, Davis JC Jr. Type I interferon correlates with clinical and serologic manifestations of systemic lupus erythematosus. Ann Rheum Dis 2005;64:1692-1697.
67. Stewart TA. Neutralizing interferon as a therapeutic approach to autoimmune disease. Citokine Growth Factor Rev 2003;14:139-154.
68. Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML, et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52:1185-1195.
69. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-678.
70. Takii Y, Nakamura M, Ito M, Yokoyama T, Komori A, Shimizu-Yoshida Y, et al. Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis. Lab Invest 2005;85:908-920.
71. Jacobsen H. Interferon-β. In: Roitt IM, Delves PJ, editors. Encyclopedia of immunology. London: Academic Press; 1992. p. 889-1.
72. van Holten J, Smeets TJ, Blankert P, Tak PP. Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann Rheum Dis 2005;64:1780-1782.
73. Wheelock EF, Sibley WA. Circulating virus, interferon and antibody after vaccination with the 17-D strain of yellow-fever virus. N Engl J Med 1965;22;273:194-198.
74. Yip YK, Pang RH, Urban C, Vilcek J. Partial purification and characterization of human gamma (immune) interferon. Proc Natl Acad Sci (USA) 1981;78:1601-1605.
75. Lawn RM, Gross M, Houck CM, Franke AE, Gray PV, Goeddel DV. DNA sequence of a major human leukocyte interferon gene. Proc Natl Acad Sci (USA) 1981;78:5435-5439.
76. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004;75:163-189.
77. Vilcek J. Interferon-γ In: Roitt IM, Delves PJ. Eds. Encyclopedia of immunology. London: Academic Press; 1992. pp 889-881.
78. Young HA, Hardy KJ. Role of interferon-gamma in immune cell regulation. J Leukoc Biol 1995;58:373-381.
79. Vilcek J, Feldmann M. Historical review: Cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci 2004;25:201-209.
80. http://search.medscape.com/drug-reference-search?newSearch=1&query Text=Interferon
81. http://www.who.int/mediacentre/factsheets/fs204/en/
82. Hui AY, Chan HL, Cheung AY, Cooksley G, Sung JJ. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther 20055;22:519-528.
83. Lin OS, Keeffe EB. Current treatment strategies for chronic hepatitis B and C. Annu Rev Med 2001;52:29-49.
84. http://www.who.int/immunization/topics/hepatitis_c/en/index.html
85. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-1578.
86. Kiyosawa K, Sodeyama T, Nakano Y, Yoda H, Tanaka E, Hayata T, et al. Treatment of chronic non-A non-B hepatitis with human interferon beta: a preliminary study. Antiviral Res 1989;12151-12161.
87. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-1500.
88. Ward RP, Kugelmas M. Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C. Am Fam Physician 2005;72:655-662.
89. Contessa G, Durelli L. Interferon-beta-1a for the treatment of multiple sclerosis. Expert Opin Biol Ther 2007;7:535-542.
90. Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med 2002;53:285-302.
91. Buttmann M, Rieckmann P. Interferon-beta1b in multiple sclerosis. Expert Rev Neurother 2007;7:227-239.
92. Jacobs L, Salazar AM, Herndon R, Reese PA, Freeman A, Josefowicz R, et al. Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet 1986;2:1411-1413.
93. Gresser I, Bourali C, Levy JP, Fontaine-Brouty-Boye D, Thomas MT. Increased survival in mice inoculated with tumor cells and treated with interferon preparations. Proc Natl Acad Sci (USA) 1969;63:51-57.
94. Goodman GR, Bethel KJ, Saven A. Hairy cell leukemia: an update. Curr Opin Hematol 2003;10:258-266.
95. Robak T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev 2006;32:365-376.
96. Hurley KE, Chapman PB. Helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b. Oncologist 2005;10:739-742.
97. Sabel MS, Sondak VK. Is there a role for adjuvant high-dose interferon-alpha-2b in the management of melanoma? Drugs 2003;63:1053-1058.
98. Kirkwood JM, Resnick GD, Cole BF. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma. Semin Oncol 1997;24 (1 Suppl 4):S16-S23.
99. Gray RJ, Pockaj BA, Kirkwood JM. An update on adjuvant interferon for melanoma. Cancer Control 2002;9:16-21.
100. Reiser M, Diehl V. Current treatment of follicular non-Hodgkin's lymphoma. Eur J Cancer 2002;38:1167-1172.
101. Solal-Celigny P. Increasing treatment options in indolent non-Hodgkin's lymphoma. Semin Oncol 2002;29(2 Suppl 6):2-6.
102. Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 2003;16:311-321.
103. Dummer R, Kempf W, Hess Schmid M, Haffner A, Burg G. Therapy of cutaneous lymphoma-current practice and future developments. Onkologie 2003;26:366-372.
104. Mellstedt H, Osterborg A, Bjorkholm M, Bjoreman M, Brenning G, Gahrton G, et al. Treatment of multiple myeloma with interferon alpha: the Scandinavian experience. Br J Haematol 1991;79(Suppl 1):21-25.
105. Anonymous. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group. Ann Intern Med 1996;124:212-222.
106. Guilhot F, Roy L, Martineua G, Guilhot J, Millot F. Immunotherapy in chronic myelogenous leukemia. Clin Lymphoma Myeloma 2007;7(Suppl 2):S64-S70.
107. Fischl MA, Finkelstein DM, He W, Powderly WG, Triozzi PL, Steigbigel RT. A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:379-384.
108. Krown SE, Li P, Von Roenn JH, Paredes J, Huang J, Testa MA. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study. J Interferon Cytokine Res 2002;22:295-303.
109. Aversa SM, Cattelan AM, Salvagno L, Crivellari G, Banna G, Trevenzoli M, et al. Treatments of AIDS-related Kaposi's sarcoma. Crit Rev Oncol Hematol 2005;53:253-265.
110. De Aloysio D, Miliffi L, Iannicelli T, Penacchioni P, Bottiglioni F. Intramuscular interferon-beta treatment of cervical intraepithelial neoplasia II associated with human papillomavirus infection. Acta Obstet Gynecol Scand 1994;73:420-424.
111. Levine LA, Elterman L, Rukstalis DB. Treatment of subclinical intraurethral human papilloma virus infection with interferon alfa-2b. Urology 1996;47:553-557.
112. Gerein V, Rastorguev E, Gerein J, Jecker P, Pfister H. Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up. Ann Otol Rhinol Laryngol 2005;114:463-471.
113. Fallani MG, Penna C, Sonni L, Gordigiani R, Cioffi M, Cesario L, et al. Treatment of female genital condylomatosis with intramuscular beta interferon. Minerva Ginecol 1991;43:595-599.
114. Zarcone R, Bellini P, Cardone G, Cardone A. Treatment of cervix condylomata with alpha-IFN leucocytar. Clin Exp Obstet Gynecol 1995;22:326-329.
115. Ship JA, Fox PC, Michalek JE, Cummins MJ, Richards AB. Treatment of primary Sjogren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res 1999;19:943-951.
116. Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum 2003;49:585-593.
117. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998;129:370-374.
118. Kötter I, Günaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behçet's disease: Review of the literature. Semin Arthritis Rheum 2004;33:320-335.
119. Çalgüneri M, Öztürk MA, Ertenli I, Kiraz , Özbalkan Z. Effects of interferon alpha treatment on the clinical course of refractory Behçet's disease: an open study. Ann Rheum Dis 2003;62:492-493.
120. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986;4:234-243.
121. Ault BH. Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med 1988;319;1397-1413.
122. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety. 1994;10:115-150.
123. Kausman D, Isenberg DA. Role of biologics in autoimmunity. Lupus 1994;3:461-466.
124. Vial T, Descotes J. Clinical toxicity of cytokines used as haemopoietic growth factors. Drug Saf 1995;13:371-406.
125. Vial T, Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology 1995;105:31-57.
126. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11, 241 patients with chronic hepatitis treated with alfa inteferon. J Hepatol 1996;24:38-47.
127. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26 (Suppl 1):112S-121S.
128. Merigan TC. Human interferon as a therapeutic agent. N Engl J Med 1988;318:1458-1460.
129. Ramos Niembro F. Autoinmunidad y enfermedades autoinumunes asociadas con el empleo de interferones. En: Ramos Niembro F, Orozco Alcalá, Eds.Terapia biológica en las enfermedades reumáticas. México: Elsevier-Masson-Doyma; 2006. pp. 345-368.
130. Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002;20:3703-3718.
131. Rönnblom LE, Alm GV, Öberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991;115:178-183.
132. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon-alpha therapy in chronic myelogeneous leukemia. J Clin Oncol 1995;13:2401-2407.
133. Papo T. Interferón alpha et auto-immunité. Rev Med Int (Paris). 2002;24(Suppl 4):501s-510s.
134. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000;43:1431-1442.
135. Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon- α. Autoimmunity 2003;36:511-518.
136. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-718.
137. Koon H, Atkins M. Autoimmunity and immunotherapy for cancer. N Engl J Med 2006;354:758-760.